Neuroprotective effect of flupirtine in prion disease

Drugs of Today

Volumn 38, Issue 1, 2002, Pages 49-58

  Schröder, Heinz C ^a   Müller, Werner E G ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUPIRTINE; MEPACRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN BCL 2; PYRIDINE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CALCIUM; GLUTATHIONE; NEUROPROTECTIVE AGENT;

CALCIUM BLOOD LEVEL; CREUTZFELDT JAKOB DISEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; NEUROPROTECTION; NEUROTOXICITY; PRION DISEASE; REVIEW; ANIMAL; METABOLISM; PATHOLOGY; PROTO ONCOGENE;

AMINOPYRIDINES; ANIMAL; CALCIUM; GENES, BCL-2; GLUTATHIONE; HUMAN; NEUROPROTECTIVE AGENTS; PRION DISEASES; SUPPORT, NON-U.S. GOV'T; ANIMALS; HUMANS;

EID: 0036124965     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.1.660505     Document Type: Review

References (74)

1. Prions
2. Creutzfeldt-Jakob disease: Assessment and management
3. Review: Creutzfeldt-Jakob disease
4. A new variant of Creutzfeldt-Jakob disease in the UK
5. Transmission to mice indicate that "new variant" CJD is caused by the BSE agent
6. Compelling transgenic evidence for transmission of bovine spongiform encephalopathy prions to humans
7. Clinical aspects of human spongi-form encephalopathies, with the exception of iatrogenic forms
8. New variant Creutzfeldt-Jakob disease: Psychiatric features
9. Pathology of variant Creutzfeldt-Jakob disease
10. Abnormal proteins in the cerebrospinal fluid of a patient with Creutzfeldt-Jakob disease following administration of human pituitary growth hormone
11. Detection of apoptosis induced DNA cleavage in scrapie-infected sheep brain
12. Programmed cell death (apoptosis) in Alzheimer's disease and Creutzfeldt-Jakob disease
13. Sc)-induced toxicity in rat cortical cell culture
14. Neurotoxicity of a prion protein fragment
15. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate
16. Structure of the recombinant full-length hamster prion protein PrP (29-231): The N terminus is highly flexible
17. Prion protein peptides induce α-helix to β-sheet conformational transitions
18. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment
19. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126
20. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment
21. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: Background, evolution, and current concerns
22. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease
23. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease
24. 14-3-3 Protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
25. 14-3-3 Proteins: Biological function and domain structure
26. Human transmissible spongiform encephalopathies
27. A novel binding assay for detection of 14-3-3 protein in cerebrospinal fluid from Creutzfeldt-Jakob patients
28. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine
29. Determination of 14-3-3 protein levels in cerebrospinal fluid from Creutzfeldt-Jakob patients by a highly sensitive capture assay
30. 14-3-3 In the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using a highly sensitive 14-3-3 protein capture assay
31. 14-3-3 Protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients
32. Mimicking dominant negative inhibition of prion replication through structure-based drug design
33. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease
34. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
35. The triaminopyridine Flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1
36. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
37. Flupirtine: A review of its pharmacological properties, and therapeutic efficacy in pain states
38. Synthese und Molekülstruktur des konstitutionell neuartigen Analgetikums Flupirtin
39. 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats
40. Immunohistochemical evidence for flupirtine acting as an antagonist on the N-methyl-D-aspartate and homocysteic acid-induced release of GABA in the rabbit retina
41. NMDA-mediated muscle relaxant action of flupirtine in rats
42. 2+ concentration
43. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist
44. Clinical experience with flupirtine in the U.S.
45. Effect of flupirtine on cell death of human umbilical vein endothelial cells induced by reactive oxygen species
46. Induction of apoptosis in cultured human retinal pigment epithelial cells is counteracted by flupirtine
47. Pharmacological intervention in age-associated brain disorders by flupirtine: Alzheimer's and prion diseases
48. Flupirtine protects both neuronal cells and lymphocytes against induced apoptotic death in vitro: Implications for treatment of AIDS patients
49. Protection of flupirtine on β-amyloid-induced apoptosis in neuronal cells in vitro: Prevention of amyloid-induced glutathione depletion
50. The role of intracellular oxidants in apoptosis
51. Glutathione
52. Flupirtine increases the levels of glutathione and Bcl-2 in hNT (human Ntera/D1) neurons: Mode of action of the drug-mediated anti-apoptotic effect
53. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126)
54. Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes
55. Sc- and HIV-1 gp120 induced neuronal cell death
56. Protection of mitochondrial integrity from oxidative stress by the triaminopyridine derivative flupirtine
57. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo
58. Bcl-2 functions in an antioxidant pathway to prevent apoptosis
59. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family
60. +) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms
61. Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients
62. Differential expression of Bax and Bcl-2 in the brains of hamsters infected with 263K scrapie agent
63. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system
64. Association of increased bcl-2 expression with rescue from tumor necrosis factor-alpha-induced cell death in the oligodendrocyte cell line OLN-93
65. Oxidant, mitochondria and calcium: An overview
66. Excitatory transmitter neurotoxicity: An overview
67. Effect of the triaminopyridine flupirtine on calcium uptake, membrane potential and ATP synthesis in rat heart mitochondria
68. Untersuchungen zur Pharmakokinetik und Biotransformation des Analgetikums Flupirtin bei Ratte und Hund
69. Flupirtine reduces functional and morphological consequences induced by global ischemia in rats
70. Flupirtine reduces functional deficits and neuronal damage after global ischemia in rats
71. Flupirtine protects against ischemic retinal dysfunction in rats
72. First therapeutic experience with flupirtine in patients with Creutzfeldt-Jakob disease